Skip to main content
. Author manuscript; available in PMC: 2019 Sep 30.
Published in final edited form as: J Trauma Acute Care Surg. 2019 Apr;86(4):617–624. doi: 10.1097/TA.0000000000002177

Figure 5. TXA alone or in combination with p38 MAPK inhibitor does not suppress the shedding of syndecan-1 induced by severe burn.

Figure 5.

Mice received intraperitoneal injection of TXA immediately after undergoing burning procedure. A group of mice received both TXA injection and topical p38 MAPK inhibitor. Plasma concentration of shed syndecan-1 was determined using ELISA. Mean and SD of syndecan-1 plasma content (ng/ml) are shown. The statistical significance of differences between sham (N=8) and burn (N=9), burn and burn + TXA (N=10), and burn and burn + TXA + p38 MAPK inhibitor (N=10) groups was determined using t-test with Welch correction.